Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Actuate Therapeutics, Inc. Common stock (ACTU)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: ACTU (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $29
1 Year Target Price $29
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -25.82% | Avg. Invested days 21 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 168.27M USD | Price to earnings Ratio - | 1Y Target Price 29 |
Price to earnings Ratio - | 1Y Target Price 29 | ||
Volume (30-day avg) 3 | Beta - | 52 Weeks Range 5.47 - 11.99 | Updated Date 08/15/2025 |
52 Weeks Range 5.47 - 11.99 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.15 |
Earnings Date
Report Date 2025-08-14 | When After Market | Estimate -0.31 | Actual -0.3 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -413.44% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 174815833 | Price to Sales(TTM) - |
Enterprise Value 174815833 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 20470500 | Shares Floating 6545119 |
Shares Outstanding 20470500 | Shares Floating 6545119 | ||
Percent Insiders 18.08 | Percent Institutions 55.09 |
Upturn AI SWOT
Actuate Therapeutics, Inc. Common stock
Company Overview
History and Background
Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing novel therapeutics for cancers that have become resistant to standard treatment. The company was founded to develop and commercialize drugs that modulate cellular stress response pathways.
Core Business Areas
- Drug Development: Actuate focuses on research and development of new cancer therapies. Main focus is on researching, developing and testing therapies.
Leadership and Structure
Dr. David R. Gandara serves as Chief Medical Officer. The company has a management team focused on clinical development and research. Actuate operates with a research and development structure.
Top Products and Market Share
Key Offerings
- elimusertib: Elimusertib is the lead product, a selective ATP-competitive inhibitor of PAK4. It is undergoing clinical trials for various cancer types. Currently there is no market share data for this product.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive, focusing on discovering, developing, and commercializing innovative therapies for a wide range of diseases, including cancer. It has a lot of regulations and compliance checks.
Positioning
Actuate Therapeutics is positioned as a clinical-stage company focused on novel cancer therapies, particularly in areas where current treatments are insufficient. Its competitive advantage lies in its unique approach of modulating cellular stress response pathways with elimusertib.
Total Addressable Market (TAM)
The total addressable market for cancer therapeutics is substantial, reaching hundreds of billions of dollars globally. Actuate is positioned to capture a portion of this market through its focus on resistant cancers and novel mechanisms of action. The specific TAM for elimusertib targets is dependent on clinical trial success and eventual market approval.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach (PAK4 inhibition)
- Clinical-stage asset (elimusertib)
- Experienced management team
Weaknesses
- Reliance on a single lead product
- High cash burn rate
- Dependence on clinical trial outcomes
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
Threats
- Clinical trial failures
- Competition from established cancer therapies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- MRTX
- AZN
- GILD
Competitive Landscape
Actuate Therapeutics is a small player in the competitive landscape of cancer therapeutics. Its competitive advantage is its novel approach, but it faces significant challenges from larger, more established companies with broader pipelines and resources.
Growth Trajectory and Initiatives
Historical Growth: The historical growth of the company is focused on research and development.
Future Projections: Future growth is dependent on clinical trial success and regulatory approvals for elimusertib. Analyst estimates are not publicly available.
Recent Initiatives: Recent initiatives include ongoing clinical trials of elimusertib in various cancer types.
Summary
Actuate Therapeutics is a clinical-stage biopharmaceutical company focusing on a novel approach to cancer therapy, specifically PAK4 inhibition. It is a promising company with a novel therapeutic approach, but with a lot of inherent risk. The company's success hinges on the success of clinical trials and its ability to secure funding and partnerships. It faces strong competition from larger, more established pharmaceutical companies and a need to diversify its product pipeline and get regulatory approvals.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Actuate Therapeutics, Inc. Common stock
Exchange NASDAQ | Headquaters Fort Worth, TX, United States | ||
IPO Launch date 2024-08-13 | CEO, President & Director Mr. Daniel M. Schmitt | ||
Sector Healthcare | Industry Biotechnology | Full time employees 10 | Website https://actuatetherapeutics.com |
Full time employees 10 | Website https://actuatetherapeutics.com | ||
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as metastatic melanoma and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.